Moffitt Cancer Center 17th Annual Clinical Breakthroughs and Challenges in Hematologic Malignancies 2022

Description

+ Include: 14 videos + 1 pdf, size: 1.83 GB

+ Target Audience: oncologist, hematologist

+ Sample video: contact me for sample video

+ Topics:

Course Syllabus.pdf
AML MDS Debate Should MRD be Used to Guide Transplant Decisions In AML and MDS.ts
AML MDS Interactive Case Discussion Using Molecular Monitoring to Guide Therapy in AML.ts
AML MDS State of the Art Frontline Management of the Higher Risk MDS Patient.ts
Hot Topics COVID-19 in Cancer Patients Outcomes and Prevention.ts
Hot Topics Managing Hematologic Toxicity from Immunotherapeutic Agents.ts
Hot Topics Pre-Leukemic Mutations in the Blood Reason to Worry.ts
Hot Topics Updates on the role of CAR-T in Lymphoma.ts
Lymphoid Malignancies Debate Should Next Generation Sequencing be Reported In All Newly Diagnosed Lymphomas.ts
Lymphoid Malignancies Interactive Case Discussion Treatment of Relapsed Refractory Diffuse Large B-cell Lymphoma.ts
Lymphoid Malignancies State of the Art Best Frontline therapy for CLL.ts
Multiple Myeloma Debate How Much is Enough (or Too Much) in Newly Diagnosed Multiple Myeloma-Triplet Therapy vs Quadruplet therapy Ken Shain.ts
Multiple Myeloma Debate How Much is Enough (or Too Much) in Newly Diagnosed Multiple Myeloma-Triplet Therapy vs Quadruplet therapy Rachid Baz.ts
Multiple Myeloma Interactive Case Discussion Novel Immune Based Therapy for Relapsed Refractory Multiple Myeloma.ts
Multiple Myeloma State of the Art BCMA CAR T-Therapy for Multiple Myeloma- Real World Experience.ts